Antibodies currently represent more than half of the total sales of all biopharmaceutical products and their market size has been growing steadily. Because nature uses antibodies to fight against diseases, they have many advantages for therapeutic and diagnostic uses such as being highly target-specific, low immunogenicity, longer half-life and faster clinical approval. Most of therapeutic antibodies are full-length, but smaller antibody fragments are gaining more attention over the last decade. Right now, antibody fragments represent 10% of approved antibody therapeutics on the market but this number is increasing exponentially. Kalyoncu Lab aims to design, discover, engineer and characterize antibody fragments for therapeutic and diagnostic applications.
Stimple SD, Kalyoncu S, Desai AA, Mogensen JE, Spang, LT, Asgreen, DJ, Staby A, Tessier PM. Sensitive detection of glucagon aggregation using amyloid fibril-specific antibodies. Biotechnology and Bioengineering. 2019; In press.
Kaleli NE, Karadag M, Kalyoncu S. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues. Proteins: Structure, Function, and Bioinformatics. 2019; doi.org/10.1002/prot.25685.
Arslan M, Karadag D, Kalyoncu S. Protein engineering approaches for antibody fragments: directed evolution and rational design approaches. Turkish Journal of Biology. 2019;43(1):1-12.
Naing SH, Kalyoncu S, Smalley DM, et al. Both positional and chemical variables control in vitro proteolytic cleavage of a presenilin ortholog. J Biol Chem. 2018;293(13):4653-4663.
Kalyoncu S, Heaner DP, Kurt Z, Bethel CM, Ukachukwu CU, Chakravarthy S, Spain JC, Lieberman RL. Enzymatic hydrolysis by transition-metal-dependent nucleophilic aromatic substitution. Nature Chemical Biology. 2016;12(12):1031-1036.
Johnson JL, Kalyoncu S, Lieberman RL. Lessons from an alpha-Helical Membrane Enzyme: Expression, Purification, and Detergent Optimization for Biophysical and Structural Characterization. Methods Mol Biol. 2016;1432:281-301.
Naing SH, Vukoti KM, Drury JE, Johnson JL, Kalyoncu S, Hill SE, Torres MP, Lieberman RL. Catalytic Properties of Intramembrane Aspartyl Protease Substrate Hydrolysis Evaluated Using a FRET Peptide Cleavage Assay. ACS Chem Biol. 2015;10(9):2166-2174.
Johnson JL, Entzminger KC, Hyun J, Kalyoncu S, Heaner DP, Morales IA, Sheppard A, Gumbart JC, Maynard JA, Lieberman RL. Structural and biophysical characterization of an epitope-specific engineered Fab fragment and complexation with membrane proteins: implications for co-crystallization. Acta Crystallogr D Biol Crystallogr. 2015;71(Pt 4):896-906.
Kalyoncu S, Hyun J, Pai JC, Johnson JL, Entzminger, K, Jain A, Heaner, DP, Morales, IA, Truskett TM, Maynard JA, Lieberman RL. Effects of protein engineering and rational mutagenesis on crystal lattice of single chain antibody fragments. Proteins. 2014;82(9):1884-1895.
Kalyoncu S, Keskin O, Gursoy A. Interaction prediction and classification of PDZ domains. BMC Bioinformatics. 2010;11:357.
Our goal is to develop antibody fragments in several formats for therapeutic and diagnostic applications. Currently, our research interests are: (1) Development of antibody fragments such as Fab, scFv, VH from full-length antibodies and their test and characterization for therapeutic or diagnostic use. (2) Several protein engineering approaches such as linker design, protein fusions and conjugates to develop next-generation antibody fragments (3) Antibody discovery for novel targets by phage display and yeast surface display
Nazlı Eda Kaleli, Murat Karadag, Sibel Kalyoncu. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues. Proteins: Structure, Function, and Bioinformatics. 2019 doi:10.1002/prot.25685.
Merve Arslan, Dilara Karadag, Sibel Kalyoncu. Protein engineering approaches for antibody fragments: directed evolution and rational design approaches. Turkish Journal of Biology. 2019 ; 43 1-12.
+90 232 299 41 00 (5181)
+90 232 299 41 68